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68 Poster Session Ihigh doseMelphalan 200 mg/M2 except 14 patients. Three patients
received Busulfan/Cytoxan/TBI (Total Body Irradiation) and 11
patients receivedMel-140/TBI. Cytogenetics studies were available
in 69/101 patients (68%). Treatment related mortality was 1% at
day 100. Complete remission was defined by negative immuno-fix-
ation. After ASCT 28/101 (28%) patients were in CR. The median
progression free survival (PFS) and overall survival (OS) was 15.6
and 50.8 months respectively. Pre and post ASCT variables (Table
1) were analyzed. Only history of prior radiation therapy (XRT) was
predictive of poor PFS and OS on univariate and multivariate anal-
ysis. Onmultivariate analysis, both status at transplant (Patients not
in CR or PR) and history of prior XRT were predictive of inferior
PFS (P 5 0.04 and\0.001, Hazard ratio of 1.6 and 3.7, respectively)
and only history of prior XRT was predictive of inferior OS (P 5
0.006, Hazard ratio of 2.5). The median time from diagnosis to
ASCTwas not influenced by history of prior therapeutic XRT.His-
tory of prior radiation therapy maintained its adverse prognostic ef-
fect independent of cytogenetics or TBI based conditioning
regimens. Complete remission post ASCTwas not predictive of im-
proved PFS or OS.
Conclusion:History of treatment with radiation therapy prior to
ASCT in AA withMM is predictive of poor PFS andOS. The cause
of the adverse impact of XRT on the outcomes after ASCT in AA
with MM is unclear at this point. This finding was unexpected
andmerits further investigation in both AA and non AAwith correl-
ative biological studies. Status at transplant of less than PR was pre-
dictive of poor outcome while CR after ASCT was not predictive of
improved PFS or OS in AA. Shorter PFS and similar OS were ob-
served in this population compared to the historical control in non
AA.184
PHASE I STUDY OF BORTEZOMIB, (BTZ) FOLLOWED BY HIGH-DOSE
MELPHALAN, (HD Mel) AND BTZ AS CONDITIONING REGIMEN FOR
TANDEM PERIPHERAL BLOOD STEM CELL TRANSPLANTS (TanPSCT)
IN PATIENTS WITH PRIMARY REFRACTORY MULTIPLE MYELOMA
(MM) AND PLASMA CELL LEUKEMIA (PCL)
Alsina, M., Alekshun, T., McIsaac-Simonelli, C., Kharfan-Dabaja, M.,
Dalton, W., Djulbegovic, B., Fernandez, H., Sullivan, D.M.,
Ayala, E., Field, T., Garrett, D., Janssen, W.E., Maddox, B.,
Perez, L.E., Kettner, D., Perkins, J., Raychaudhuri, J., Anasetti, C.H.
Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Background:Novel treatment approaches are paramount for pa-
tients with primary refractory MM and PCL, because despite HD
chemotherapy, patient median survival is approximately 12 months.
The proteasome inhibitor BTZ sensitizes myeloma cells to melpha-
lan both in vitro and in vivo by a mechanism not well understood. In
this study we examine the effects of BTZ, followed by BTZ andHD
Mel as conditioning regimen for TanPSCT in this poor-risk group.
Methods: Patients with primary refractory MM or PCL received 2
cycles of BTZ at 1.3 mg/m2. followed by HDMel (200 mg/m2) and
one dose of BTZ at 0.7 mg/m2, 1.0 mg/m2 or 1.3 mg/m2, as a con-
ditioning regimen prior to TanPSCT. The dose of BTZ was given
immediately after the last dose of HDMel. Bone marrow(BM) sam-
ples were collected at baseline, on day 4 and after 2 cycles of BTZ,
and at 3 months after TanPSCT, for GEP and Fanconi anemia(FA)
pathway genes assessment. Results:To date, 17 patients have been
enrolled and treated, and 11 patients are evaluable for response.Me-
dian age is 59 years (46–70) with the following myeloma distribu-
tion: 55% IgA and 45% IgG. FISH analysis showed the
following: del 13q (44%), t (4; 14) (11%), t (11; 14) (11%), trisomy
11 (11%), and polyploid (11%); standard karyotype was normal in
88% of patients and complex karyotype in 12%. Median time to
WBC engraftment (days) was 13 and 12 after the first and second
transplant, respectively. Median time to plt engraftment (days)
was 20 and 17, after the first and second transplant, respectively.
There were no dose limiting toxicities. Observed grade 3 toxicities
were related to the conditioning regimen and similar to those ob-
served with HDMel alone. One patient developed diffuse alveolar
hemorrhage after the first cycle of BTZ, which resolved, but was re-
moved from study. After 2 cycles of BTZ, 45% of patients achieved
PR, and 55% had stable disease. Overall response rate at 3 monthsfrom the second transplant increased to 90%(CR5 36%, VGPR5
27% andPR5 27%). Only 1 patient developed progressive disease
after the first transplant. Evaluations of BM samples byGEP and FA
pathway gene expression are underway. Conclusions: Single agent
BTZ induced responses in 45% and the combination of HD Mel
and BTZ as conditioning regimen for TanPSCT was well tolerated
and improved response rates to 90%. These early results suggest
that this regimen is very active in this poor-risk group. A Phase II
study is underway.185
EFFICIENT STEM CELL MOBILIZATION IN LENALIDOMIDE TREATED
MULTIPLE MYELOMA PATIENTS CAN BE ACHIEVED BY MOBILIZATION
WITH DCEP (DEXAMETHASONE, CYCLOPHOSPHAMIDE, ETOPOSIDE,
CISPLATINUM) FOLLOWED BY HIGH-DOSE G-CSF
Badin, S.M.1, Lendvai, N.2, Gounder, S.K.1, Rowley, S.2, Donato, M.2,
Goldberg, S.2, Pecora, A.2, McBride, L.H.2, Schmidt, L.2,
Donadio, K.A.2, McNeil, A.2, Siegel, D.S.2. 1UMDNJ, Newark, NJ;
2HUMC, Hackensack, NJ.
High dose chemotherapy with autologous stem cell rescue
(ASCT) remains a standard therapy for multiple myeloma patients
who can tolerate it. Lenalidomide in combination with dexametha-
sone has emerged as a highly effective oral induction regimen. Con-
sequently, an increasing number of patients are receiving this
therapy prior to undergoing ASCT. However, patients treated
with lenalidomide were recently reported to have had significantly
reduced stem cell yield upon mobilization with G-CSF alone1.
We report our experience with patients treated with lenalidomide
who subsequently underwent stem cell mobilization at our institu-
tion since 2006. Our goal for collection is 10–12 106 CD341 cells
to allow for two-three transplants using at least 4 106 CD341 cells
per transplant. Our experience with patients who received lenalido-
mide-based therapy and then underwent mobilization with high
dose G-CSF (n 5 5) confirmed the above observation. The mean
yield was 6  106 CD341 cells, with only 1 of 5 patients reaching
the mobilization goal. In contrast, patients treated with lenalido-
mide-based therapy but mobilized with DCEP chemotherapy and
high dose G-CSF (n5 9) had significantly higher CD341 cell yield
and required shorter pheresis. This group’s mean yield was 26.1 
106 CD341 cells, all 9 patients reached themobilization goal of.10
 106 CD341 cells, 3 of the patients were pheresed for 1 day and 4
patients were pheresed for 2 days.
We have previously reported DCEP to be well tolerated, and
have predictable kinetics regarding initiation of collection of stem
cells. Our regimen, which can be administered on an outpatient ba-
sis, consists of 40 mg dexamethasone IV over 15 minutes  4 days,
cyclophosphamide 500 mg/m2, etoposide 40 mg/m2 (capped at 75
mg), and cisplatin 15 mg/m2 (capped at 25 mg), all continuous IV
infusions over 24 h  4 days, with G-CSF starting 24–48 h after
completion of chemotherapy, administered SQ at 5 mcg/kg  6
days followed by 10 mcg/kg daily until pheresis is completed.
In conclusion, this regimen is highly efficacious, offers excellent
stem cell yields and predictable collection kinetics, in patients
treated with lenalidomide-based therapy prior to ASCT.
1Kumar S. et al. Impact of lenalidomide therapy on stem cell mo-
bilization and engraftment post-peripheral blood stem cell trans-
plantation in patients with newly diagnosed myeloma. Leukemia.
2007 Sep;21(9):2035–42.186
BORTEZOMIB ADDED TO HIGH-DOSE CYCLOPHOSPHAMIDE DURING
STEM CELL MOBILIZATION IS SAFE AND PROVIDES EFFECTIVE DISEASE
CONTROL IN CHEMOTHERAPY-REFRACTORY MULTIPLE MYELOMA
Voralia, M.1, Fibich, C.1, Katzman, M.1, Danyluk, P.1, George, T.1,
Doell, H.1, Evjen, A.1, vanden Berghe, J.2, Briggs, S.1. 1Saskatchewan
Cancer Agency, Saskatoon, SK, Canada; 2University of Saskatchewan,
Saskatoon, SK, Canada.
Poster Session I 69Introduction: Autologous stem cell transplantation is accepted
therapy for most younger patients with multiple myeloma (MM)
following steroid-based induction therapy. Use of dose-intense sal-
vage chemotherapy, such as D-PACE, in steroid-refractory MM
may adversely affect stem cell harvesting. Bortezomib (Bor), an
agent with a novel mechanism of action against MM, may be syner-
gistic to alkylating agents, and does not affect stem cell yield in pre-
treated patients.We piloted the addition of Bor to high-dose cyclo-
phosphamide (Cy) during stem cell harvesting in a series of patients
refractory to D-PACE salvage therapy. Patients and Methods: 17
MM patients refractory to 3 or more cycles of steroid-based induc-
tion therapy received 2 cycles of D-PACE in prior to proceeding to
autologous stem cell harvesting. 7 patients achieved adequate cytor-
eduction and proceeded to high-dose Cy (3 g/m2) and G-CSF plus
SCF stimulation for mobilization. In 10 patients not achieving ad-
equate disease cytoreduction, Bor was added to the mobilization
regimen prior to high-dose Cy. Response assessment included
time to stem cell harvest, number of CD34 cells harvested, disease
response, and effect on hematologic parameters. Results: Toxic-
ities arising from D-PACE were similar in both groups. The com-
bination Bor/Cy mobilization regimen did not lead to increased
symptomatic toxicity. Grade 3/4 thrombocytopenia occurred in 6/
10 patients receiving combination therapy. No significant bleeding,
peripheral neuropathy, or skin rash occured. The average CD341
stem cell harvest in both groups was .5.0  106/kg., and favored
the combination group. Time to adequate stem cell harvest was sim-
ilar between the groups. The harvested product from the Bor/Cy
group consistently demonstrated \2% cells bearing plasma cell
markers by flow cytometry. 1 patient in each group failed to mobi-
lize sufficient stem cells for an adequate harvest. Bone marrow
plasma cell content following Bor/Cy harvesting decreased in all as-
sessed patients. Time to engraftment was similar in both groups.
Data on post-transplant disease control and survival will be pre-
sented. Presence of unfavorable cytogenetics or ISS stage at diagno-
sis did not appear to affect response to Bor/Cy therapy.
Conclusion: The addition of Bor to high-dose Cy during stem
cell mobilization does not increase toxicity or decrease stem cell
harvest yield or quality, and achieves adequate disease reduction
in patients refractory to salvage chemotherapy.187
FLUDARABIN AND CYCLOPHOSPHAMIDE BASED NON-MYELOABLATIVE
CONDITIONING REGIMENS IN THE PATIENTS ALLOGRAFTED FOR
RECURRENT/REFRACTORY MALIGNANT LYMPHOPROLIFERATIVE
DISORDERS
Raida, L.1, Vondrakova, J.1, Faber, E.1, Papajik, T.1, Indrak, K.1,
Langova, K.2. 1University Hospital, Olomouc, Czech Republic; 2Medical
School of Palacky University, Olomouc, Czech Republic.
Background: Non-myeloablative conditionings combined
fludarabin and cyclophosphamide (FLU-CY) with or without
antithymocyte globulin (ATG) and low-dose total body irradiation
(LD-TBI) may be used in the patients allografted for malignant
lymphomas. Significant immunosuppressionwithout severe toxicity
allows to engraft donor cells responsible for desirable graft versus
lymphoma (GvL) reaction. Patients and Methods: 20 patients
with the age median of 49 (range 27–58) years were allografted
for relapsed and/or refractory malignant lymphoproliferative dis-
eases: 5 B chronic lymphocytic leukemia (B-CLL), 4Hodgkin’s
lymphoma (HL), 8 B and 3 T non-Hodgkin’s lymphoma
(NHL). 9 patients (45%) were conditioned with FLU-CY. ATG
only was added to FLU-CY in 6 cases (30%), ATG and LD-TBI
in 5 ones (25%). 9 patients (45%) received the graft from sibling,
6 (30%)matched unrelated and 5 ones (25%)mismatched unrelated
donor. Peripheral blood and bone marrow were the source of stem
cells in 17 (85%) and 3 cases (15%), respectively. The median of
transfused CD341 cells was 5.03 (range 2.5–8.8) 106/kg of recip-
ient body weight. Graft versus host disease (GvHD) prophylaxis
with cyclosporine A (CSP-A) only was administered to 10 recipients
(50%). Mycophenolate mofetil (MMF) and methotrexate (MTX)
were added to CSP-A in 9 (45%) and 1 cases (5%), respectively.
The median of posttransplant follow-up was 1.6 (range 0.3–5.7)
years. Results: All recipients engrafted and non-hematologicaltoxicity did not exceed the grade I. 10 ones (50%) developed acute
GvHD. Chronic GvHD was observed in 10 of 18 assessable cases
(55.6%). All patients (100%) achieved complete remission (CR) of
lymphoma. 4 ones (20%) relapsed and 2 of them (10%) died of tu-
mor progression. 7 recipients (35%) died of posttransplant compli-
cations. Estimated 5-year event-free (EFS) and overall survival (OS)
were 27% and 29%, respectively. Conclusion: The results con-
firmed a possibility to cure recurrent/refractory lymphoma by
GvL reaction without the previous significant tumor burden reduc-
tion.Nevertheless, GvHDand associated complications still remain
the main cause of posttransplant morbidity and mortality.
Supported by the Ministry of Education of the Czech Republic
(MSM-6198959205).188
SINGLE INSTITUTION’S OUTCOMES FOR FIRST TRANSPLANT AS SAL-
VAGE THERAPY FOR HODGKIN’S LYMPHOMA
Shafer, J.A.1,3, Heslop, H.E.1,2,3, Carrum, G.1,2, Kamble, R.1,2,
Myers, G.D.1,3, Leung, K.S.1,3, Bollard, C.M.1,2,3, Krance, R.A.1,2,3
1Baylor College ofMedicine; 2Baylor College ofMedicine; 3Baylor College
of Medicine, Houston, TX.
Survival Rates for patients diagnosed with Hodgkin’s lymphoma
(HL) approaches 90% irrespective of stage at initial diagnosis. But
for patients with primary refractory or relapsed disease the out-
comes are less favorable. High dose chemotherapy with stem cell
rescue has been shown to be the preferred salvage approach, with
overall survival rates ranging from 30–65%, compared to conven-
tional chemotherapy. Risk factors for poor outcomes include early
relapse and primary refractory disease and it is suggested that these
groupsmay benefit from allogenic transplant.However, the outlook
for patients with chemo-resistant disease is poor and it is unclear if
these patients receive any benefit from stem cell transplant. Here we
evaluate outcomes of patients who have received stem cell trans-
plant at our institution for relapsed or refractory Hodgkin’s disease.
A retrospective review of 42 patients who received their initial trans-
plant for Hodgkin’s disease between October of 1997 and June of
2007 at the Center for Cell and Gene Therapy in Houston, Texas
was performed. Indications for transplant included refractory dis-
ease at primary diagnosis or relapsed disease. 30 patients received
high dose chemotherapy with autologous stem cell rescue and 12
patients received an allogeneic HSCT. Indications for allogeneic
HSCT included chemorefractory disease and/or bone marrow in-
volvement of HL. The median age of the patients was 23.5 (range
12–60 years). Median time of follow up was 3 years (range 3 months
to 9 years). 5 year overall survival (OS) was 66% and progression
free survival (PFS) was 56%. Of the 7 patients transplanted (2
auto and 5 allo) with chemotherapy resistant disease only one pa-
tient survives (\1 year follow-up). The remaining 6 died within 3
years of SCT primarily due to disease progression. When these
highest risk patients with chemotherapy resistant disease are ex-
cluded in the analysis the OS and PFS after SCT is 76% and 66%
respectively. Our data supports the dismal results of patients with
chemo resistant disease, whereas patients with chemo-sensitive dis-
ease have a good chance of cure with HSCT.189
NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
TO TREAT HIGH RISK HEAVILY PRETREATED MULTIPLE
Moreb, J.S., Wirk, B.M., Cogle, C., Jamieson, K.J., Hsu, J.,
Wingard, J.R. University of Florida, Gainesville, FL.
Allogeneic stem cell transplantation (SCT) can induce long term
remissions and some cures in multiple myeloma (MM). High treat-
ment related mortality (TRM) associated with such treatment mo-
dality has been the reason behind exploring non-myeloblative
conditioning regimens (NMA) in these patients. As part of a pro-
spective study evaluating NMA for hematologic malignancies in
our institution, 12 MM patients were enrolled between 2000–
2006. All patients were transplanted as either part of initial
